- Conditions
- Asthma
- Interventions
- omalizumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Palmdale, California • San Diego, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 8,374
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 114
- States / cities
- Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more
- Conditions
- Choroid Neovascularization, Age-Related Macular Degeneration
- Interventions
- AGN 211745, Ranibizumab 500µg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Age Related Macular Degeneration
- Interventions
- HLX04-O, ranibizumab
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 23 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- bendamustine, navitoclax, rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Fountain Valley, California • Hudson, Florida • Lawrenceville, Georgia + 10 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Copanlisib Hydrochloride, Nivolumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Hays, Kansas + 12 more
- Conditions
- Leukemia, Non-Hodgkin's Lymphoma, NHL
- Interventions
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy, Antibody Therapy, Monoclonal Antibody Therapy
- Drug · Procedure
- Lead sponsor
- Cambridge Antibody Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Bethesda, Maryland
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Intravenous (Human), 10%
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 24 Months and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
- Interventions
- ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
- Biological · Radiation · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 3
- States / cities
- Evanston, Illinois • New York, New York • Portland, Oregon
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Spinocerebellar Ataxias
- Interventions
- Intravenous Immune Globulin (IVIG)
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Chronic Idiopathic Thrombocytopenic Purpura
- Interventions
- Gammaplex, intravenous immunoglobulin
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Drug · Radiation
- Lead sponsor
- Amer Zureikat
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Melanoma
- Interventions
- Nivolumab, Ipilimumab + nivolumab, Pembrolizumab, Dabrafenib + trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
- Interventions
- Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
- Drug · Device
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- CD20+ Follicular Lymphoma
- Interventions
- Duvelisib, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Hackensack, New Jersey + 2 more
- Conditions
- Sarcopenia
- Interventions
- Not listed
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 70 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
- Interventions
- Rituximab, Cytarabine, Methotrexate, Procarbazine, Vincristine, low-dose whole-brain radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab and Etoposide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina